Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

in Oracle a recursive CTE unfortunately cannot be marked with the recursive keyword (despite the ANSI standard) and in Postgres it must be marked with "recursive". In Oracle a CTE is inherently ...

Abstract: In this study, we investigate the prescribed-time non-singular terminal sliding mode control (TSMC) for high-order nonlinear systems. Initially, a novel time-varying, high-order terminal ...

At Microsoft Build 2025, we announced the public preview of SQL Server 2025. Built on a foundation of best-in-class security, performance, and availability, SQL Server 2025 empowers customers to ...

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.